Inductive Bio has integrated its advanced ADMET prediction models into Anthropic's Claude ecosystem, enhancing the capabilities available to drug discovery scientists.
On June 30, 2026, Inductive Bio announced its partnership with Anthropic, enabling their ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) prediction models to be accessed directly through Claude. This integration allows scientists to leverage these predictive models seamlessly within their existing workflows, facilitating natural language interaction to evaluate key drug properties for various chemical structures.
The introduction of this connector addresses a significant challenge in small molecule drug discovery, where balancing a drug’s efficacy with its ADMET properties is crucial yet often resource-intensive. Inductive Bio's models have been independently validated as leading-edge, having outperformed over 370 submissions in a recent competitive evaluation. By integrating these capabilities into Claude, the connector democratizes access to sophisticated predictive tools, empowering scientists to refine their drug hypotheses more effectively.
Ben Birnbaum, Co-Founder and CTO of Inductive, emphasized the importance of this integration, stating that it allows scientists to incorporate ADMET predictions into their discussions, thereby enhancing their design processes. This step not only improves access to cutting-edge technology but also illustrates the potential of AI in transforming drug discovery methodologies.
With a focus on data privacy, the connector ensures that chemical structures submitted via Claude are not retained or used for model training. This initiative highlights Inductive Bio's commitment to advancing drug discovery while safeguarding scientists' data integrity.